Stephanie O'Brien Net Worth

Stephanie O'Brien biography

Stephanie Monaghan O'Brien J.D. serves as Independent Director of the Company. Ms. O’Brien has been a member of the investment team at Morningside since 1997. She has served as a director of Aduro Biotech Inc. since 2011, and as a director of numerous private nonclinical and clinical-stage companies developing drugs across a broad spectrum of therapeutic focus, including oncology and immunotherapy, and has extensive experience providing operational and management oversight to venture-backed technology companies. Prior to joining Morningside, Ms. O’Brien spent nine years as a corporate lawyer with Hale and Dorr in its Boston and Washington, D.C. offices, working primarily on public offerings, venture capital finances and start-up companies. She previously worked at Chase Manhattan Bank, working in international portfolio analysis. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law.

What is the salary of Stephanie Brien?

As the Independent Director of Apellis Pharmaceuticals Inc, the total compensation of Stephanie Brien at Apellis Pharmaceuticals Inc is $247,035. There are 11 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.

How old is Stephanie Brien?

Stephanie Brien is 61, she's been the Independent Director of Apellis Pharmaceuticals Inc since 2013. There are 1 older and 22 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.

What's Stephanie Brien's mailing address?

Stephanie's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.

Insiders trading at Apellis Pharmaceuticals Inc

Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois y Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.

What does Apellis Pharmaceuticals Inc do?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Apellis Pharmaceuticals Inc executives and stock owners

Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Cedric Francois,
  President, Chief Executive Officer, Co-Founder, Director
• Lukas Scheibler,
  Chief Innovation Officer
• Federico Grossi,
  Chief Medical Officer
• Thomas Lackner,
  Senior Vice President, Head of Europe
• Pascal Deschatelets,
  Co-Founder, Chief Operating Officer
• Timothy Sullivan,
  Chief Financial Officer, Treasurer
• Dr. Cedric Francois,
  Co-Founder, Pres, CEO & Director
• Timothy E. Sullivan,
  Chief Financial Officer
• Dr. Pascal Deschatelets Ph.D.,
  Co-Founder & Chief Scientific Officer
• Adam J. Townsend,
  Chief Commercial Officer
• Gerald Chan,
  Independent Chairman of the Board
• Stephanie O'Brien,
  Independent Director
• Alec Machiels,
  Independent Director
• A. Sinclair Dunlop,
  Independent Director
• Alec Machiels J.D., MBA,
  Co-Founder & Independent Director
• Sam Martin,
  IR Contact Officer
• Paul Fonteyne,
  Independent Director
• Adam Townsend,
  Chief Commercial Officer
• David Watson,
  General Counsel, Vice President of Corporate Development
• Nicole Perry,
  Vice President - Finance
• Victoria Brown,
  Senior Vice President, Program Team Lead – Systemic Chronic
• David O. Watson,
  Gen. Counsel
• Meredith Kaya,
  Sr. VP, Investor Relations & Strategic Fin.
• James G. Chopas CPA,
  VP, Corp. Controller & Chief Accounting Officer
• Dr. Lukas Scheibler M.D., Ph.D.,
  Chief Innovation Officer
• Karen Lewis,
  Chief People Officer
• Nur Nicholson,
  Chief Technical Operations Officer
• Dr. Federico Grossi M.D., Ph.D.,
  Co-Founder & Chief Medical Officer
• Nur Nicholson,
  Chief Technical Officer
• Karen Lewis,
  Chief People Officer
• Venture Investments Ltd Mor...,
  10% owner
• Lucia Celona,
  See Remarks
• Ahmad Sadr,
  See Remarks
• Jeffrey Eisele,
  Chief Development Officer
• Mark Jeffrey De Long,
  Chief Business & Strat Officer
• James George Chopas,
  VP/Chief Accounting Officer
• Caroline Baumal,
  Chief Medical Officer